Differential aminoacylase expression in neuroblastoma

Area of Science:

• Biochemistry
• Oncology
• Molecular Biology

Background:

• Neuroblastoma is the most common pediatric extracranial solid tumor.
• High-risk neuroblastomas often feature MYCN amplification and BDNF/TrkB signaling, but these markers are present in only 25% of cases.
• Identifying novel biomarkers and therapeutic targets is crucial for improving neuroblastoma treatment outcomes.

Purpose of the Study:

• To investigate the role of aminoacylase 1 (ACY1), aspartoacylase (ASPA), and aminoacylase 3 (ACY3) in neuroblastoma.
• To determine if these enzymes function as tumor suppressors in neuroblastoma, similar to their proposed roles in other cancers.
• To explore the expression patterns and prognostic significance of aminoacylases in neuroblastoma.

Main Methods:

• Examined aminoacylase expression in various neuroblastoma cell lines with different TrkB and MYCN statuses.
• Assessed aminoacylase localization within cells (cytosolic, membrane-associated, nuclear).
• Analyzed aminoacylase expression changes upon treatment with neural differentiation agents.
• Utilized bioinformatics to correlate aminoacylase expression with patient survival data.

Main Results:

• Each aminoacylase (ACY1, ASPA, ACY3) exhibited distinct cellular localization.
• ACY1 expression was upregulated by neural differentiation agents in specific cell lines.
• ACY3 expression was higher in TrkB-positive, MYCN-amplified neuroblastoma lines.
• High ACY3 expression correlated with poor prognosis, while low ACY1 or ASPA expression also indicated poor prognosis.
• ACY1 and ACY3 were detected in primary neuroblastoma tumors.

Conclusions:

• Aminoacylase expression is dysregulated in neuroblastoma.
• ACY1, ASPA, and ACY3 represent potential biomarkers for neuroblastoma prognosis.
• The distinct expression patterns and prognostic correlations suggest these enzymes could be novel therapeutic targets.